Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX ANNOUNCES TWO NEW BOARD MEMBERS

ROCHESTER, NY - Vaccinex, Inc. today announced the appointment of Alan Crane and Gerald VanStrydonck to the company's Board of Directors.

Alan Crane is the Chief Executive Officer and Chairman of the Board of Momenta Pharmaceuticals, a biotechnology company located in Cambridge, MA. Mr. Crane was previously Senior Vice President, Global Corporate Development, at Millennium Pharmaceuticals where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities. During his tenure, Mr. Crane built one of the industry's leading corporate development groups, forged strategic alliances that brought over $2 billion of funding to Millennium, and licensed or acquired 19 products. Previously, Mr. Crane was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little. Mr. Crane received his B.A., M.A. and M.B.A. from Harvard University.

Gerald VanStrydonck is a former managing partner of PricewaterhouseCoopers, LLP with over 30 years of experience providing tax and other financial advice to technology, manufacturing and services companies. Mr. VanStrydonck is currently the Senior Vice President and Chief Financial Officer of Sigma Marketing Group, a marketing consulting group located in Rochester, NY. He serves as a board member of Genesee Valley Trust and St. John Fisher College. Mr. VanStrydonck received a B.B.A. from St. John Fisher College and an M.B.A. from State University of New York at Buffalo.

"We are pleased to add Alan and Gerry as the newest members of our Board of Directors," said Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex. "Both of these individuals bring broad business experience and have assisted in the growth and success of early-stage companies. We anticipate that they will provide valuable guidance and assistance as Vaccinex expands our antibody services business and therapeutic product development activities."

Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Therapeutic antibodies have become one of the largest and fastest growing sectors of biotechnology, currently representing approximately 20% of all drugs in the biotechnology pipeline. Vaccinex's antibody discovery platform is one of the only library-based antibody technologies that can directly express complete, fully human antibodies in mammalian cells. The company is commercializing this technology by offering antibody discovery services to clients worldwide and is developing its own proprietary therapeutic products, initially focused on cancer. The firm is headquartered in Rochester, New York and currently has over 30 employees. For additional information, please visit the company's website at www.vaccinex.com.

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX ANNOUNCES TWO NEW BOARD MEMBERS ROCHESTER, NY - Vaccinex, Inc. today announced the appointment of Alan Crane and Gerald VanStrydonck to the company's Board of Directors. Alan Crane is the Chief Executive Officer and Chairman of the Board of Momenta Pharmaceuticals, a biotechnology company located in Cambridge, MA. Mr. Crane was previously Senior Vice President, Global Corporate Development, at Millennium Pharmaceuticals where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities. During his tenure, Mr. Crane built one of the industry's leading corporate development groups, forged strategic alliances that brought over $2 billion of funding to Millennium, and licensed or acquired 19 products. Previously, Mr. Crane was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little. Mr. Crane received his B.A., M.A. and M.B.A. from Harvard University. Gerald VanStrydonck is a former managing partner of PricewaterhouseCoopers, LLP with over 30 years of experience providing tax and other financial advice to technology, manufacturing and services companies. Mr. VanStrydonck is currently the Senior Vice President and Chief Financial Officer of Sigma Marketing Group, a marketing consulting group located in Rochester, NY. He serves as a board member of Genesee Valley Trust and St. John Fisher College. Mr. VanStrydonck received a B.B.A. from St. John Fisher College and an M.B.A. from State University of New York at Buffalo. "We are pleased to add Alan and Gerry as the newest members of our Board of Directors," said Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex. "Both of these individuals bring broad business experience and have assisted in the growth and success of early-stage companies. We anticipate that they will provide valuable guidance and assistance as Vaccinex expands our antibody services business and therapeutic product development activities." Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Therapeutic antibodies have become one of the largest and fastest growing sectors of biotechnology, currently representing approximately 20% of all drugs in the biotechnology pipeline. Vaccinex's antibody discovery platform is one of the only library-based antibody technologies that can directly express complete, fully human antibodies in mammalian cells. The company is commercializing this technology by offering antibody discovery services to clients worldwide and is developing its own proprietary therapeutic products, initially focused on cancer. The firm is headquartered in Rochester, New York and currently has over 30 employees. For additional information, please visit the company's website at www.vaccinex.com. Back to News Archive Copyright © 2008 Vaccinex, Inc.